Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
26 hedge funds and large institutions have $2.4M invested in Deep Medicine Acquisition Corp. Rights in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
86% more capital invested
Capital invested by funds: $1.29M → $2.4M (+$1.11M)
10% less funds holding
Funds holding: 29 → 26 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$160K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$32.7K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$30K |
| 4 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$13.2K |
| 5 |
HF
HRT Financial
New York
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$238K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$29.1K |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$14.8K |
| 4 |
Walleye Capital
New York
|
-$14.5K |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$11.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| $11.5K | – | – | – |
|
|
MP
27
Mangrove Partners
Greenwich,
Connecticut
| – | -$238K | -1,485,437 | Closed |
|
|
RCM
28
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| – | -$11.9K | -70,000 | Closed |
|
|
AA
29
Ancora Advisors
Cleveland,
Ohio
| – | -$722 | -5,155 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$56 | -400 | Closed |
|
DMAQR Hedge Fund Activity: Q3 2023 in Review
26 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q3 2023, worth a combined $2.4M — up 86% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DMAQR and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Cowen and Company, adding an estimated $160K. The largest seller was Mangrove Partners, exiting entirely with an estimated $238K sold.
- 26 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q3 2023, down from 29 in Q2 2023.
- Funds reported $2.4M of Deep Medicine Acquisition Corp. Rights stock for Q3 2023, up 86% quarter-over-quarter.
- 1 fund opened new Deep Medicine Acquisition Corp. Rights positions in Q3 2023 and 4 closed out, a net change of -3 holders.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q3 2023 was Cowen and Company, an estimated $160K added.
- The largest Deep Medicine Acquisition Corp. Rights seller in Q3 2023 was Mangrove Partners, an estimated $238K sold.
Based on aggregated 13F filings for Q3 2023.